首頁 > 市場調查報告書 > 製藥

再生醫學

幹細胞庫市場規模、佔有率和成長分析（按來源、服務類型、應用和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1897671

幹細胞庫市場規模、佔有率和成長分析（按來源、服務類型、應用和地區分類）－2026-2033年產業預測

Stem Cell Banking Market Size, Share, and Growth Analysis, By Source (Placental Stem Cells, Adipose Tissue-Derived Stem Cells), By Service Type (Sample Preservation & Storage, Sample Analysis), By Application, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月25日 | 出版商:

SkyQuest | 英文 188 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，幹細胞庫市場規模將達到 116.5 億美元，到 2025 年將達到 137.8 億美元，到 2033 年將達到 528.8 億美元，在預測期（2026-2033 年）內，複合年成長率為 18.3%。

幹細胞庫市場經歷了顯著成長，這主要得益於冷凍保存技術的進步和細胞庫的發展。單株抗體的廣泛應用和幹細胞療法的引入也是推動這一趨勢的重要因素。幹細胞應用領域的持續研究，特別是用於治療神經退化性疾病和心血管疾病的造血幹細胞移植，提供了廣泛的機會。此外，組織庫和生物庫在保存成人組織和幹細胞以用於各種臨床應用方面發揮著至關重要的作用。再生醫學領域的創新，例如誘導多功能細胞（iPS細胞），為以往無法治癒的疾病帶來了希望。此外，晚育趨勢的日益成長促使越來越多的父母從嬰兒身上獲取幹細胞以備將來醫療之需，這凸顯了臍帶血庫的重要性。

幹細胞庫市場促進因素

幹細胞庫市場正經歷著向成人幹細胞，特別是骨髓和脂肪組織來源幹細胞的顯著轉變。這些來源的幹細胞來源豐富，並且在倫理上可以取代胚胎幹細胞。此外，微創採集方法的創新，例如骨髓穿刺採集，正在改善患者的整體體驗，並提高人們對幹細胞庫的興趣和接受度。幹細胞庫的豐富性、倫理考量以及採集技術的進步共同推動了市場發展，並促進了幹細胞庫服務的普及和整合。

幹細胞庫市場限制因素

由於幹細胞研究和儲存相關的監管環境不斷變化，幹細胞庫市場面臨巨大的挑戰。儘管各國政府制定了嚴格的法規來維護安全和倫理標準，但這些要求的複雜性卻為幹細胞庫公司帶來了挑戰。持續的監管變化和不確定性會阻礙市場成長，因為公司必須靈活應對這些波動。這種動態環境會造成障礙，最終影響市場參與企業的有效運作和創新能力，並進一步加劇他們應對複雜法律規範的困難。

幹細胞庫市場趨勢

幹細胞庫市場正經歷顯著成長，這主要得益於造血幹細胞移植（HSCT）需求的不斷成長。 HSCT擴大被用於治療骨髓惡性腫瘤和某些遺傳性疾病。 HSCT手術成功率的不斷提高凸顯了獲取幹細胞來源的重要性，無論這些幹細胞來自私人幹細胞庫還是捐贈者登記庫。隨著消費者和醫療服務提供者對幹細胞庫益處的認知不斷加深，對可靠且易於獲取的幹細胞方案的需求也隨之激增。醫療技術的進步和研究的不斷深入進一步推動了這一趨勢，預示著該領域擁有蓬勃發展的未來。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Cordlife（Singapore）
Cryo-Cell International（US）
LifeCell International（India）
StemCyte（US）
Global Cord Blood（Hong Kong）
Smart Cells International（UK）
Vita34（Germany）
CryoHoldco（US）
Cellerant Therapeutics, Inc.（US）
StemCell Technologies Inc.（Canada）
Regenexx（US）
Athersys, Inc.（US）
Mesoblast Limited（Australia）
Cytori Therapeutics, Inc.（US）
OrthoGenics（US）
Panthera Biopartners（UK）
Stemson Therapeutics（US）
Lonza Group AG（Switzerland）
Macopharma（France）
Cure Cell（Turkey）
LifeBankUSA（US）
Biolife Plasma Services, LLC（US）
NexImmune, Inc.（US）

簡介目錄

Product Code: SQMIG35H2294

Stem Cell Banking Market size was valued at USD 11.65 Billion in 2024 and is poised to grow from USD 13.78 Billion in 2025 to USD 52.88 Billion by 2033, growing at a CAGR of 18.3% during the forecast period (2026-2033).

The stem cell banking market is witnessing significant growth, largely driven by advancements in cryopreservation and the preparation of cell banks. The escalating popularity of monoclonal antibodies and the adoption of stem cell therapies are also key contributors to this trend. Ongoing research in stem cell applications, especially in hematopoietic stem cell transplants for neurodegenerative and cardiovascular diseases, presents vast opportunities. Additionally, tissue banks and biobanks play an essential role in the preservation of adult tissues and stem cells for diverse clinical uses. Innovations in regenerative medicine, such as induced pluripotent stem cells, offer hope for previously untreatable conditions. Furthermore, the rising trend of late parenthood emphasizes the importance of umbilical cord blood banking, as parents seek to secure their infants' stem cells for future medical needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Stem Cell Banking market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Stem Cell Banking Market Segments Analysis

Global Stem Cell Banking Market is segmented by Source, Service Type, Application, and region. Based on Source, the market is segmented into Placental Stem Cells (PSCS), Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS), and Other Stem Cell Sources. Based on Service Type, the market is segmented into Sample Preservation and Storage, Sample Analysis, Sample Processing, and Sample Collection and Transportation. Based on Application, the market is segmented into Personalized Banking Applications, Research Applications, and Clinical Applications. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Stem Cell Banking Market

The stem cell banking market is experiencing a significant shift towards adult stem cells, particularly those derived from bone marrow and adipose tissue. These sources provide greater accessibility and serve as ethically viable alternatives to embryonic stem cells. Additionally, innovations in minimally invasive collection methods, such as needle extraction of bone marrow, are enhancing the overall patient experience, contributing to a growing interest and acceptance of stem cell banking. This combination of accessibility, ethical considerations, and advancements in collection techniques is driving the market forward, fostering increased adoption and integration of stem cell banking services.

Restraints in the Stem Cell Banking Market

The stem cell banking market faces significant challenges due to the ever-evolving regulatory landscape surrounding stem cell research and storage. Governments impose stringent regulations to maintain safety and ethical standards, but the complexity of these requirements poses difficulties for stem cell banking companies. The ongoing changes and uncertainties in regulations can hinder market growth, as companies must remain agile and responsive to adapt to these fluctuations. This dynamic environment can create obstacles, ultimately impacting the ability of market participants to operate effectively and innovate, further complicating their efforts to navigate the intricate regulatory framework.

Market Trends of the Stem Cell Banking Market

The Stem Cell Banking market is experiencing significant growth driven by the rising demand for hematopoietic stem cell transplantation (HSCT), which is increasingly employed in treating blood malignancies and certain genetic disorders. The growing success rates of HSCT procedures underscore the importance of accessible stem cell sources, whether from personal banks or donor registries. As awareness about the benefits of stem cell banking expands among consumers and healthcare providers alike, the need for reliable and readily available stem cell options is surging. This trend is further fueled by advancements in medical technologies and the expansion of research, promising a vibrant future for the sector.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Landscape
Case Study Analysis
Technology Analysis
Supply Chain Analysis
Value Chain Analysis
PESTEL Analysis

Stem Cell Banking Market by Source

Market Overview
Placental Stem Cells (PSCS)
Adipose Tissue-Derived Stem Cells (ADSCS)
Bone Marrow-Derived Stem Cells (BMSCS)
Human Embryo-Derived Stem Cells (HESCS)
Dental Pulp-Derived Stem Cells (DPSCS)
Other Stem Cell Sources

Stem Cell Banking Market by Service Type

Market Overview
Sample Preservation and Storage
Sample Analysis
Sample Processing
Sample Collection and Transportation

Stem Cell Banking Market by Application

Market Overview
Personalized Banking Applications
Research Applications
- Disease Treatment Studies
- Life Science Research
- Drug Discovery
Clinical Applications
- Hematopoietic Disorders
- Autoimmune Disorders
- Other Diseases

Stem Cell Banking Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Cordlife (Singapore)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cryo-Cell International (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LifeCell International (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
StemCyte (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Global Cord Blood (Hong Kong)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Smart Cells International (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vita34 (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CryoHoldco (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellerant Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
StemCell Technologies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regenexx (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athersys, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesoblast Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cytori Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OrthoGenics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Panthera Biopartners (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stemson Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Macopharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cure Cell (Turkey)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LifeBankUSA (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biolife Plasma Services, LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NexImmune, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments